FG-4592 (Roxadustat)

Catalog No. A11237

FG-4592 is a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in CKD anemia.
  • Singh C, .et al. Serine and 1-carbon metabolism are required for HIF-mediated protection against retinopathy of prematurity, JCI Insight, 2019, Jul 25;4(14) PMID: 31341109
  • Hideaki Nakamura, .et al. Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions, PLoS One, 2018, 13(2): e0192136 PMID: 29466367
  • Singh C, .et al. 3-Hydroxypyruvate Destabilizes Hypoxia Inducible Factor and Induces Angiostasis, Invest Ophthalmol Vis Sci, 2018, Jul 2;59(8):3440-3448 PMID: 30025089
  • George Hoppe, .et al. Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity, Proc Natl Acad Sci U S A, 2016, May 3; 113(18): E2516–E2525 PMID: 27091985
Catalog Num A11237
M. Wt 352.3
Formula C19H16N2O5
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 808118-40-3
Synonyms FG4592, ASP1517
SMILES CC1=NC(=C(C2=C1C=C(C=C2)OC3=CC=CC=C3)O)C(=O)NCC(=O)O
FG-4592 is a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in CKD anemia.
Targets
HIF α prolyl hydroxylase (Cell-free assay)
In vitro DMSO 70 mg/mL (198.67 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 28.38 mL 141.92 mL 283.85 mL
0.5 mM 5.68 mL 28.38 mL 56.77 mL
1 mM 2.84 mL 14.19 mL 28.38 mL
5 mM 0.57 mL 2.84 mL 5.68 mL

*The above data is based on the productmolecular weight 352.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.